CERT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CE

Mkt Cap

$1.43B

Volume

1.64M

Next Earnings

November 5th

Loading chart

CE

CERTCertara, Inc. Common Stock

CERT

Pay with—

Available Balance0.00

CE

Mkt Cap

$1.43B

Volume

1.64M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine DemandThe global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.GlobeNewswire Inc. · Sep 23, 2026

The Market Just Told You Which Layer Of AI Biology It Is Paying ForRecent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.GlobeNewswire Inc. · Sep 3, 2026

[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global in silico clinical trials market, valued at USD 1.84 billion in 2025, is projected to grow to USD 8.94 billion by 2035 at a 15.2% CAGR. Growth is driven by high failure rates in traditional clinical trials, regulatory acceptance of computational evidence, advances in AI and digital twins, and ethical concerns about animal testing. North America dominates the market while Asia Pacific shows the fastest growth.GlobeNewswire Inc. · Jun 26, 2026

Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings announcement. Certara reported declining services revenue (down 4% YoY to $57.2M) and bookings (down 14% YoY to $66.6M), citing softer performance from major customers and exiting its regulatory business. The stock fell 19% on the news, dropping from $6.31 to $5.13 per share on May 11, 2026.GlobeNewswire Inc. · Jun 19, 2026

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesLaw firm Johnson Fistel is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors who suffered losses following the company's May 2026 earnings report disclosing declining services revenue and bookings, along with execution challenges. The investigation was further prompted by the announcement of CFO John Gallagher's resignation effective July 14, 2026. Investors who purchased Certara securities and experienced losses are encouraged to contact the firm.GlobeNewswire Inc. · Jun 18, 2026

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItThe AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.Benzinga · Jun 16, 2026

CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law FirmThe Schall Law Firm announced an investigation into Certara, Inc. (NASDAQ: CERT) for potential securities law violations following the company's May 11, 2026 Q1 earnings report. Certara disclosed declining services revenues and bookings, attributing the weakness to softer performance from Tier 1 customers in MIDD services. The stock fell 19% on the announcement, prompting the law firm to seek shareholders who suffered losses.GlobeNewswire Inc. · May 24, 2026

CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsLaw firm Kirby McInerney LLP is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings report, which revealed a 4% decline in services revenue and 14% decline in services bookings, along with softer Tier 1 customer performance and exit from the regulatory business. The stock price fell 19% on the news.GlobeNewswire Inc. · May 18, 2026

Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsightThe biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.GlobeNewswire Inc. · Apr 27, 2026

Clinical Trial Software Research Report 2026: $2.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe clinical trial software market is expected to grow from $1.32 billion in 2025 to $2.53 billion by 2030, with a CAGR of 13.8%. Growth drivers include increased digitization, adoption of AI and cloud-based solutions, virtual and decentralized trials, and enhanced data security focus. Major players are innovating with unified trial solutions and strategic acquisitions to strengthen their market positions.GlobeNewswire Inc. · Apr 24, 2026

to start trading

CE

CERTCertara, Inc. Common Stock

CERT

Pay with—

Available Balance0.00

Your PositionYou don't own any CERT yet.

Related Tickers

Earnings